Physician profile
Simone Nelson
NPI 1407578834
$5,947.55
in general payments reported to CMS, 2019-2025
28 companies · $2,547 in 2025
The $2,547 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $259 · 2023: $1,224 · 2024: $1,918 · 2025: $2,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,688.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $743.37 | 2023-2025 | |
| Indivior INC. | $699.27 | 2023-2025 | Sublocade |
| Abbvie INC. | $679.28 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $661.25 | 2022-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $541.96 | 2023-2025 | Xtampza, Belbuca |
| Forte Bio-Pharma LLC | $500.50 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Novo Nordisk INC | $492.75 | 2022-2025 | Wegovy, Saxenda |
| Lundbeck LLC | $358.10 | 2024-2025 | Vyepti |
| Scilex Pharmaceuticals INC. | $286.60 | 2022-2025 | Ztlido |
| Virtus Pharmaceuticals LLC | $160.45 | 2023-2025 | Levorphanol Tartrate |
| Vertex Pharmaceuticals Incorporated | $148.94 | 2024-2025 | |
| Medtronic, INC. | $91.77 | 2023-2025 | Inceptiv, Intellis Adaptivestim |
| Boston Scientific Corporation | $78.42 | 2024-2025 | General - Pain Management |
| Tonix Medicines, INC. | $70.98 | 2025 | Tonmya |
| Valinor Pharma, LLC | $57.65 | 2025 | Movantik |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $53.67 | 2024-2025 | Zepbound |
| Biohaven Pharmaceutical Holding Company Ltd. | $46.23 | 2022 | |
| Nevro Corp. | $43.41 | 2022-2024 | Senza |
| Hikma Pharmaceuticals USA | $36.28 | 2023 | Kloxxado |
| Intra-Sana Laboratories | $35.64 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Currax Pharmaceuticals LLC | $31.65 | 2022-2023 | Onzetra Xsail, Contrave |
| Braeburn INC. | $24.82 | 2024 | Brixadi |
| Azurity Pharmaceuticals, INC. | $21.16 | 2023 | Horizant |
| Teva Pharmaceuticals USA, INC. | $19.39 | 2024 | Ajovy |
| Almatica Pharma LLC | $18.48 | 2023 | Gralise |
| Allergan, INC. | $16.05 | 2022 | |
| Orexo US, INC. | $14.81 | 2024 | Zubsolv |
| International Rehabilitative Sciences, INC | $14.67 | 2024 | Rs 4i Plus Sequential Stimulator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simone Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.